Loading...
Loading...
FIXX| Name | Value |
|---|---|
| Revenues | 0.4M |
| Cost of Revenue | 0.6M |
| Gross Profit | -0.2M |
| Operating Expense | 31.2M |
| Operating I/L | -30.8M |
| Other Income/Expense | 1.5M |
| Interest Income | 1.5M |
| Pretax | -29.3M |
| Income Tax Expense | 5.7M |
| Net Income/Loss | -35.0M |
Homology Medicines, Inc. is a genetic medicines company specializing in developing treatments for rare genetic diseases. The company's proprietary platform utilizes human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines for various genetic disorders through gene therapy or nuclease-free gene editing. Their lead product candidate, HMI-102, is in Phase 2 pheNIX clinical trial for treating phenylketonuria (PKU) in adults. Additionally, they are developing HMI-103 for pediatric PKU patients, HMI-202 for metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 for paroxysmal nocturnal hemoglobinuria.
